 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || UCB1381 / UCB
Trial completion date, Trial primary completion date: A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (clinicaltrials.gov) - Dec 13, 2024
P1/2, N=152, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
- || UCB1381 / UCB
Trial completion date, Trial primary completion date: A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (clinicaltrials.gov) - Jan 23, 2023
P1/2, N=152, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Jul 2025 Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
- ||| UCB1381 / UCB
Enrollment open: A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (clinicaltrials.gov) - Mar 28, 2022
P1/2, N=152, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025 Not yet recruiting --> Recruiting
- |||| UCB1381 / UCB
New P1/2 trial: A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (clinicaltrials.gov) - Mar 13, 2022
P1/2, N=152, Not yet recruiting, Sponsor: UCB Biopharma SRL